Delcath Systems Inc patents expiration
1. Hepzato patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11241522 | DELCATH SYSTEMS INC | Apparatus for removing chemotherapy compounds from blood |
Nov, 2032
(9 years from now) | |
| US10369264 | DELCATH SYSTEMS INC | Apparatus for removing chemotherapy compounds from blood |
Nov, 2032
(9 years from now) | |
| US10098997 | DELCATH SYSTEMS INC | Apparatus for removing chemotherapy compounds from blood |
Nov, 2032
(9 years from now) | |
| US11633528 | DELCATH SYSTEMS INC | Apparatus for removing chemotherapy compounds from blood |
Nov, 2032
(9 years from now) | |
| US11083831 | DELCATH SYSTEMS INC | Filter and frame apparatus and method of use |
Dec, 2032
(9 years from now) | |
| US10195334 | DELCATH SYSTEMS INC | Filter and frame apparatus and method of use |
Jan, 2033
(9 years from now) | |
| US9314561 | DELCATH SYSTEMS INC | Filter and frame apparatus and method of use |
Feb, 2034
(10 years from now) | |
| US9707331 | DELCATH SYSTEMS INC | Apparatus for removing chemotherapy compounds from blood |
Sep, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 14, 2030 |
Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient
Market Authorisation Date: 14 August, 2023
Treatment: A percutaneous hepatic perfusion procedure for treating a patient with uveal melanoma with unresectable hepatic metastases
Dosage: POWDER;INTRA-ARTERIAL
More Information on Dosage
HEPZATO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic